Thursday, November 20, 2014
Recap: CardioCell Hosts Event During AHA Scientific Sessions
CardioCell Brings Together Its Scientific Advisory Board and Clinical Trials Investigators and Administrators
CardioCell held a reception for its Scientific Advisory Board Members and clinical trials investigators and administrators during the AHA Scientific Sessions in Chicago. It was exceptional to assemble in one room so many key cardiology opinion leaders, including:
- Dr. Allen Anderson, Principal Investigator for CardioCell’s chronic heart failure clinical trial at Northwestern University and Cardiologist and Medical Director of the Center for Heart Failure at Northwestern’s Bluhm Cardiovascular Institute
- Dr. Javed Butler, CardioCell Scientific Advisory Board Member and Chief of the Cardiology Division, Stony Brook Heart Institute
- Dr. Stephen Epstein, CardioCell’s Scientific Advisory Board Chair and Director, Translational and Vascular Biology Research, MedStar Heart Institute, MedStar Washington Hospital Center, as well as Clinical Professor of Medicine, Georgetown University
- Dr. Mihai Gheorghiade, CardioCell Scientific Advisory Board Member and Professor of Medicine and Surgery, Associate Director, Director of Experimental Therapeutics, Center for Cardiovascular Innovation at the Northwestern University Feinberg School of Medicine, as well as Adjunct Professor, Duke University
- Dr. Arshed Quyyumi, CardioCell Scientific Advisory Board Member and Co-Director, Emory Clinical Cardiovascular Research Institute (ECCRI), Co-Director, Emory Cardiovascular Research and Professor of Cardiology, Emory University
- Dr. Robert Wilensky, CardioCell Scientific Advisory Board Member and Director, Interventional Cardiology, University of Pennsylvania School of Medicine and Professor of Medicine, University of Pennsylvania
CardioCell’s CEO Sergey Sikora thanked guests for their commitment to CardioCell’s vision of developing breakthough stem cell therapies for cardiovascular indications. He then introduced the Scientific Advisory Board Chair.
Dr. Epstein offered his perspective on his more than three decades of research on applying stem cells to cardiology indications. Much has been learned from failures in the early days, and he is very optimistic about new approaches like CardioCell’s hypoxically grown stem cells that are intravenously introduced to patients. He celebrated attendees for their efforts in advancing this next phase of clinical development.
The Scientific Advisory Board had a chance to discuss new ideas for 2015.